US 11,834,503 B2
Anti-lag-3 antibodies and compositions
Michael Monrad Grandal, Ballerup (DK); Vikram Kjøller Bhatia, Charlottenlund (DK); Torben Gjetting, Jyllinge (DK); Camilla Fröhlich, København Ø (DK); Gunther Roland Galler, Jyllinge (DK); Michael Kragh, Copenhagen N (DK); Ivan David Horak, West Orange, NJ (US); Thomas Bouquin, Alleroed (DK); and Mikkel Wandahl Pedersen, Alleroed (DK)
Assigned to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Lianyungang (CN)
Filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang (CN)
Filed on Jun. 7, 2022, as Appl. No. 17/834,497.
Application 17/834,497 is a division of application No. 16/340,855, granted, now 11,390,676, previously published as PCT/EP2017/076188, filed on Oct. 13, 2017.
Claims priority of provisional application 62/407,678, filed on Oct. 13, 2016.
Prior Publication US 2022/0363757 A1, Nov. 17, 2022
Int. Cl. C07K 16/28 (2006.01); C12N 15/85 (2006.01); A61P 37/04 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C12N 15/85 (2013.01)] 20 Claims
 
1. Isolated nucleic acid molecule(s) comprising a nucleotide sequence that encodes a heavy chain sequence, and a nucleotide sequence that encodes a light chain sequence, of an anti-LAG-3 antibody or an antigen-binding portion thereof that comprises the H-CDR1-3 and L-CDR1-3 amino acid sequences of:
a) SEQ ID NOs: 41, 42, 43, 44, 45, and 40, respectively;
b) SEQ ID NOs: 35, 36, 37, 38, 39, and 40, respectively;
c) SEQ ID NOs: 35, 42, 46, 44, 47, and 40, respectively;
d) SEQ ID NOs: 48, 49, 50, 51, 47, and 52, respectively;
e) SEQ ID NOs: 53, 54, 55, 44, 45, and 40, respectively;
f) SEQ ID NOs: 56, 57, 58, 59, 60, and 61, respectively; or
g) SEQ ID NOs: 62, 63, 64, 65, 66, and 67, respectively.